The radiopharmaceutical market is accelerating, driven by growing clinical demand and the emergence of new diagnostic and molecular therapy agents.
Advertorial by
However, scanners and clinical expertise are only part of the equation. Without a reliable supply of short-lived radiopharmaceuticals, examinations cannot proceed as planned, and innovation cannot translate into routine care.
The challenge for the UK is therefore not simply to expand imaging capability, but to rethink and modernise the manufacturing infrastructure that underpins it. As demand grows and new tracers and therapies enter clinical practice, radiopharmaceutical production must evolve to keep pace. Supply cannot become the limiting factor.
This is the rationale behind the new 8X radiopharmacy developed by Siemens Healthineers in Dunstable. This £26m investment will bolster the long-term supply of PET radiopharmaceuticals in the UK, making it more consistent, reliable, and regular, supporting the growth in clinical demand.
Designed as the UK’s first 8X radiopharmacy, the facility will deliver eight times the production capacity of a single radiopharma site today. The facility has been designed to supply radiopharmaceuticals at a scale sufficient to meet demand across the UK, supporting both current requirements and future growth.
PET radiopharmaceuticals have extremely short half-lives. Production, quality control, transportation, and administration must therefore operate as a tightly coordinated process. Unlike conventional medicines, these products cannot be manufactured and stored for extended periods. They must reach PET/CT centres within a tightly managed timeframe, whether they are established agents used in routine practice or new tracers progressing through clinical trials and commercialisation.
The 8X radiopharmacy has been purpose-built with these requirements in mind. It will house two high-energy cyclotrons, multiple clean rooms and hot cells, purpose-built dispatch areas and an extensive quality-control laboratory. All critical equipment and systems are designed with multiple back-ups, embedding redundancy and operational resilience throughout the site.
Its strategic location in Dunstable, with proximity to the M1, has also been selected to support efficient logistics and enable same-day delivery to PET/CT centres nationwide. This combination of production capacity, quality-control capability, built-in redundancy, and efficient distribution is intended to strengthen the radiopharmaceutical supply chain on which PET/CT services depend.
For the NHS, this matters because radiopharmaceutical supply is part of the clinical pathway. Without the appropriate tracer arriving at the right place, at the right time, an examination cannot take place as planned. Long-term confidence in diagnostic capacity therefore depends on more than scanners and skilled professionals. It also requires a regular, reliable supply of high-quality radiopharmaceuticals.
The clinical opportunity is expanding. PSMA tracers are advancing prostate cancer detection, while amyloid and tau tracers are providing new insights into Alzheimer’s disease. At the same time, theranostics is bringing imaging and therapy together, enabling clinicians to identify a disease target and subsequently treat it with greater precision.
The new 8X radiopharmacy is designed to support this next wave of innovation. Alongside strengthening the supply of existing PET radiopharmaceuticals, its scale and infrastructure will support the introduction of next-generation diagnostic and molecular therapy agents.
Realising that opportunity will require earlier and closer collaboration across the sector. Pharmaceutical companies developing new tracers need manufacturing partners capable of producing agents reliably and at scale. NHS providers need confidence that innovation will be supported by the necessary production, quality-assurance, and distribution infrastructure. Clinicians and researchers need dependable access to radiopharmaceuticals for both clinical trials and routine care.
The facility builds on more than 20 years of UK radiopharmaceutical experience for Siemens Healthineers and the wider expertise of a global network of more than 60 radiopharmacies. That combination of UK investment and international manufacturing experience will be increasingly important as new diagnostic and therapeutic agents move towards clinical practice.
The 8X radiopharmacy should therefore be viewed as more than a manufacturing development. It is an investment in the infrastructure needed to support reliable PET/CT services and the next generation of molecular imaging and therapy. Above all, it is intended to give the NHS, and the patients it serves, greater confidence that access to critical diagnostics can keep pace with clinical demand, today and in the future.
Discover how the 8X radiopharmacy is helping build the infrastructure needed for the next generation of nuclear medicine.
